Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Pancreas ; 41(2): 186-94, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22129531

ABSTRACT

OBJECTIVES: The aims of this study were to characterize the proteome of normal pancreatic juice, to analyze the effect of secretin on the normal proteome, and to compare these results with published data from patients with pancreatic cancer. METHODS: Paired pancreatic fluid specimens (before and after intravenous secretin stimulation) were obtained during endoscopic pancreatography from 3 patients without significant pancreatic pathology. Proteins were identified and quantified by mass spectrometry-based protein quantification technology. The human RefSeq (NCBI) database was used to compare the data in samples from patients without pancreatic disease with published data from 3 patients with pancreatic cancer. RESULTS: A total of 285 proteins were identified in normal pancreatic juice. Ninety had sufficient amino acid sequences identified to characterize the protein with a high level of confidence. All 90 proteins were present before and after secretin administration but with altered relative concentrations, usually by 1 to 2 folds, after stimulation. Comparison with 170 published pancreatic cancer proteins yielded an overlap of only 42 proteins. CONCLUSIONS: Normal pancreatic juice contains multiple proteins related to many biological processes. Secretin alters the concentration but not the spectrum of these proteins. The pancreatic juice proteome of patients without pancreatic disease and that of patients with pancreatic cancer differ markedly.


Subject(s)
Biomarkers, Tumor/analysis , Pancreatic Diseases/metabolism , Pancreatic Juice/chemistry , Pancreatic Neoplasms/chemistry , Proteins/analysis , Proteomics , Adult , Cholangiopancreatography, Endoscopic Retrograde , Chromatography, Liquid , Computational Biology , Female , Humans , Indiana , Pancreatic Juice/drug effects , Predictive Value of Tests , Proteomics/methods , Secretin/administration & dosage , Spectrometry, Mass, Electrospray Ionization , Tandem Mass Spectrometry
2.
Alcohol Clin Exp Res ; 35(12): 2216-25, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21790668

ABSTRACT

BACKGROUND: Alcohol is a significant risk factor for the development of hepatocellular carcinoma (HCC). To date, no rodent model has demonstrated the formation of hepatic neoplasia in the setting of chronic alcohol consumption alone. METHODS: We investigated whether rats selectively bred for high alcohol preference (P rats), allowed free access to water, or water and 10% (v/v) alcohol, for 6, 12, or 18 months, develop hepatic neoplasia. RESULTS: At necropsy, liver tumor incidence and multiplicity were significantly increased in 18-month alcohol-consuming versus water-consuming P rats. These data were confirmed histologically by glutathione-S-transferase pi-class (GSTp) staining. Phosphorylated mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 (MAPK/ERK) staining was also increased in the sinusoidal lining cells within livers of alcohol-consuming versus water only P rats. In addition, cytochrome p450IIE1 (CYP2E1) mRNA, protein expression/activity, and intrahepatic oxidative stress were significantly increased in alcohol-consuming P rat livers versus water only. In contrast, acetaldehyde dehydrogenase expression decreased in alcohol-consuming versus water only P rats. No significant difference in alcohol dehydrogenase expression was detected. CONCLUSIONS: These data demonstrate that chronic alcohol consumption is associated with hepatic neoplasia, MAPK/ERK activation, increased CYP2E1 activity, and intrahepatic oxidative stress in P rats. As these rats are well characterized as a model of alcoholism, these findings identify a novel rodent model of alcohol or "alcoholism"-induced liver neoplasia.


Subject(s)
Alcohol Drinking/pathology , Carcinoma, Hepatocellular/chemically induced , Ethanol/toxicity , Liver Neoplasms/chemically induced , Animals , Carcinoma, Hepatocellular/pathology , Cytochrome P-450 CYP2E1/metabolism , Ethanol/administration & dosage , Liver Neoplasms/pathology , Male , Mitogen-Activated Protein Kinases/metabolism , Models, Animal , Oxidative Stress/drug effects , Rats
3.
Pancreas ; 40(2): 260-4, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21404459

ABSTRACT

UNLABELLED: To determine if the level of transforming growth factor α (TGF-α) in the pancreatic fluid (PF) can diagnose intraductal papillary mucinous neoplasm (IPMN) versus other cystic lesions of the pancreas in patients. METHODS: Pancreatic fluid was prospectively obtained from patients during routine endoscopy and/or operation at Indiana University Hospital. Pancreatic fluid TGF-α levels were analyzed by enzyme-linked immunosorbent assay. Intraductal papillary mucinous neoplasm tissue was also analyzed by TGF-α immunohistochemistry. RESULTS: Sixty-nine fluid samples from 58 patients with the following pathologically confirmed pancreatic disorders were analyzed: IPMN (26 patients), serous cystadenoma (6), mucinous cystic neoplasm (9), pseudocysts (5), non-IPMNY associated pancreatic ductal adenocarcinoma (6), and sphincter of Oddi dysfunction (6). There was no significant difference between the mean PF-TGF-α levels in each category or between different dysplastic grades of IPMN. However, of all the diagnoses examined, only IPMN demonstrated PF-TGF-α levels greater than 95 pg/mL. In low-grade IPMN specimens, TGF-α immunohistochemistry correlated with enzyme-linked immunosorbent assay levels. CONCLUSIONS: The mean PF-TGF-α levels are not significantly different in IPMN lesions compared with those in other cystic pancreatic lesions, pancreatic ductal adenocarcinoma, or sphincter of Oddi dysfunction. However, PF-TGF-α levels more than 95 pg/mL may be useful in diagnosing IPMN. This assertion requires prospective validation.


Subject(s)
Biomarkers, Tumor/analysis , Carcinoma, Pancreatic Ductal/diagnosis , Neoplasms, Cystic, Mucinous, and Serous/diagnosis , Pancreatic Juice/immunology , Pancreatic Neoplasms/diagnosis , Transforming Growth Factor alpha/analysis , Adult , Aged , Aged, 80 and over , Analysis of Variance , Carcinoma, Pancreatic Ductal/immunology , Carcinoma, Pancreatic Ductal/pathology , Diagnosis, Differential , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunohistochemistry , Indiana , Male , Middle Aged , Neoplasm Staging , Neoplasms, Cystic, Mucinous, and Serous/immunology , Neoplasms, Cystic, Mucinous, and Serous/pathology , Pancreatic Neoplasms/immunology , Pancreatic Neoplasms/pathology , Predictive Value of Tests , Prognosis , Prospective Studies , Up-Regulation , Young Adult
4.
J Am Coll Surg ; 210(5): 779-85, 786-7, 2010 May.
Article in English | MEDLINE | ID: mdl-20421049

ABSTRACT

BACKGROUND: As compared with open distal pancreatectomy (ODP), laparoscopic distal pancreatectomy (LDP) affords improved perioperative outcomes. The role of LDP for patients with pancreatic ductal adenocarcinoma (PDAC) is not defined. STUDY DESIGN: Records from patients undergoing distal pancreatectomy (DP) for PDAC from 2000 to 2008 from 9 academic medical centers were reviewed. Short-term (node harvest and margin status) and long-term (survival) cancer outcomes were assessed. A 3:1 matched analysis was performed for ODP and LDP cases using age, American Society of Anesthesiologists (ASA) class, and tumor size. RESULTS: There were 212 patients who underwent DP for PDAC; 23 (11%) of these were approached laparoscopically. For all 212 patients, 56 (26%) had positive margins. The mean number of nodes (+/- SD) examined was 12.6 +/-8.4 and 114 patients (54%) had at least 1 positive node. Median overall survival was 16 months. In the matched analysis there were no significant differences in positive margin rates, number of nodes examined, number of patients with at least 1 positive node, or overall survival. Logistic regression for all 212 patients demonstrated that advanced age, larger tumors, positive margins, and node positive disease were independently associated with worse survival; however, method of resection (ODP vs. LDP) was not. Hospital stay was 2 days shorter in the matched comparison, which approached significance (LDP, 7.4 days vs. ODP, 9.4 days, p = 0.06). CONCLUSIONS: LDP provides similar short- and long-term oncologic outcomes as compared with OD, with potentially shorter hospital stay. These results suggest that LDP is an acceptable approach for resection of PDAC of the left pancreas in selected patients.


Subject(s)
Carcinoma, Pancreatic Ductal/surgery , Laparoscopy , Pancreatectomy , Pancreatic Neoplasms/surgery , Aged , Carcinoma, Pancreatic Ductal/pathology , Cohort Studies , Female , Humans , Length of Stay , Male , Middle Aged , Pancreatic Neoplasms/pathology , Patient Selection , Retrospective Studies , Survival Rate , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...